A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Trial Profile

A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2016

At a glance

  • Drugs Afatinib (Primary)
  • Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 10 Jul 2013 Planned initiation date changed from 1 Feb 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
    • 10 Apr 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top